Page last updated: 2024-12-11

azlocillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6479523
CHEMBL ID1537
CHEBI ID2956
SCHEMBL ID34150
MeSH IDM0002078

Synonyms (58)

Synonym
BRD-K60663764-236-02-1
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[[((r)-2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, (2s,5r,6r)-
BPBIO1_000817
PRESTWICK3_000821
azlocillin
C06839
37091-66-0
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DB01061
D02339
azlocillin (usan/inn)
BSPBIO_000741
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-((r)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
einecs 253-348-2
6-((r)-2-(2-oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
azlocilline [inn-french]
azlocilina [inn-spanish]
azlocillinum [inn-latin]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2s-(2alpha,5alpha,6beta(s*)))-
CHEBI:2956 ,
2,2-dimethyl-6beta-[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid
azlocillinum
azlocilina
azlocilline
j01ca09
nsc-758227
CHEMBL1537
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2s)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;azlocillin
A823527
hum6h389w0 ,
azlocillin [usan:inn:ban]
unii-hum6h389w0
nsc 758227
EPITOPE ID:141185
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(r)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(((2r)-2-(((2-oxoimidazolidin-1-yl)carbonyl)amino)-2-phenylacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
azlocillin [inn]
azlocillin [mi]
azlocillin [vandf]
azlocillin [who-dd]
azlocillin [mart.]
azlocillin [usan]
SCHEMBL34150
DTXSID1022639
AKOS025402328
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
AC-8140
JTWOMNBEOCYFNV-NFFDBFGFSA-N
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-((r)-2-(2-oxoimidazolidine-1-carboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DS-3291
Q510154
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2r)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
gtpl12260
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-6-[[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, [2s-[2a,5a,6b(s*)]]-
D81792
EN300-7382797

Research Excerpts

Overview

Azlocillin is a semisynthetic acylureidopenicillin with increased activity against most strains of Pseudomonas aeruginosa. It is an important antibiotic for the management of complex gram-negative infections.

ExcerptReferenceRelevance
"Azlocillin is a semisynthetic acylureidopenicillin with increased activity against most strains of Pseudomonas aeruginosa. "( Treatment of serious Pseudomonas infections with azlocillin.
Beville, R; Holmes, B; Mogabgab, WJ; Olive, S; Pauling, B; Pollock, B, 1983
)
1.96
"Azlocillin is a new semisynthetic penicillin with a broad spectrum of antibacterial activity. "( Azlocillin: a new broad spectrum penicillin.
Sanders, CC, 1983
)
3.15
"Azlocillin is an important acylureido penicillin antibiotic for the management of complex gram-negative infections particularly those caused by Pseudomonas species. "( The novel therapeutic implications of azlocillin's dose-dependent pharmacokinetics: contributing physiologic mechanisms and a prospective, cross-over designed trial.
Delgado, FA; Spilman, PS; Stout, RL; Watson, AJ; Whelton, A, 1987
)
1.99

Effects

Alocillin has a low degree of plasma protein binding: 30% to 40% depending on concentrations. It should therefore be useful for preoperative parenteral treatment of infected cholesteatomas in those cases which cannot be controlled by local therapy.

Azlocillin has a low degree of plasma protein binding: 30% to 40% depending on concentrations. It should therefore be useful for preoperative parenteral treatment of infected cholesteatomas.

ExcerptReferenceRelevance
"Azlocillin has a low degree of plasma protein binding: 30% to 40% depending on concentrations."( [Clinical pharmacokinetics of azlocillin].
Haegel, C; Singlas, E, 1984
)
1.28
"Azlocillin has a broad spectrum particularly against pseudomonas and should therefore be useful for preoperative parenteral treatment of infected cholesteatomas in those cases which cannot be controlled by local therapy. "( [Antimicrobial effectiveness of azlocillin in cholesteatoma in parenteral administration].
Mertens, J; Ullmann, U; Wustrow, J, 1988
)
2
"Azlocillin has a low degree of plasma protein binding: 30% to 40% depending on concentrations."( [Clinical pharmacokinetics of azlocillin].
Haegel, C; Singlas, E, 1984
)
1.28
"Azlocillin plasma levels have been assayed by a rapid, sensitive and precise high performance liquid chromatographic method."( [Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications].
Bartolozzi, G; Marianelli, L; Rosselli, P; Valenza, T,
)
1.76
"Azlocillin has a broad spectrum particularly against pseudomonas and should therefore be useful for preoperative parenteral treatment of infected cholesteatomas in those cases which cannot be controlled by local therapy. "( [Antimicrobial effectiveness of azlocillin in cholesteatoma in parenteral administration].
Mertens, J; Ullmann, U; Wustrow, J, 1988
)
2

Toxicity

ExcerptReferenceRelevance
"631 patients treated with azlocillin were evaluated for adverse reactions."( The safety and tolerance of azlocillin.
Parry, MF, 1985
)
0.86
"2%) experienced adverse local reactions and 92 patients (14."( The tolerance and safety of azlocillin.
Parry, MF, 1983
)
0.56

Pharmacokinetics

The possible therapeutic implications of azlocillin's dose dependency were evaluated by undertaking a six-day randomized, prospective, cross-over design study. Systemic and urinary pharmacokinetic studies of the disposition of az Locillin were performed in seven male and six female healthy volunteers.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated by a computer program based on a two compartment model."( [The effect of continuous arteriovenous hemofiltration on the pharmacokinetics of azlocillin in anuric patients].
Eberhardt, B; Krupp, A; Leuwer, M; Schmidt, H, 1990
)
0.5
" Pharmacokinetic parameters were calculated by noncompartmental methods."( Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.
Barriere, SL; Catlin, DH; Frost, RW; Noe, A; Orlando, PL, 1990
)
0.5
" trimenon, the pharmacokinetic dates after single and repeated applications of 4 g azlocillin have been evaluated."( [The pharmacokinetics of azlocillin after single and multiple intravenous injections during the third trimester].
Brandstädt, A; Peiker, G; Schröder, S; Voigt, R; Weidt, I, 1988
)
0.8
"The first pharmacokinetic data are reported of azlocillin injected intramuscularly to adult probands."( Pharmacokinetics of azlocillin after intramuscular application.
Holá, V; Novák, L; Polívková, L, 1986
)
0.85
" The possible therapeutic implications of azlocillin's dose dependency were evaluated by undertaking a six-day randomized, prospective, cross-over design study to evaluate the pharmacokinetic disposition of the drug during a 3-g q4h (typically used in adults) regimen versus a 5-g q8h regimen."( The novel therapeutic implications of azlocillin's dose-dependent pharmacokinetics: contributing physiologic mechanisms and a prospective, cross-over designed trial.
Delgado, FA; Spilman, PS; Stout, RL; Watson, AJ; Whelton, A, 1987
)
0.81
"The pharmacokinetic profile of piperacillin and azlocillin after multiple-dose administration to healthy volunteers was studied."( Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers.
Nye, L; Polk, RE; Poynor, W; Tartaglione, TA; Vishniavsky, N, 1986
)
0.78
"The pharmacokinetic characteristics of azlocillin were compared in 7 children with cystic fibrosis (CF) and 6 children without this disease who were all treated for infectious diseases."( Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
Bergan, T; Michalsen, H, 1986
)
0.86
"In this paper pharmacokinetic data of acylureidopenicillins (azlocillin and piperacillin) in pregnant women in the last trimenon are compared with those from nonpregnant controls."( Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy.
Peiker, G; Schröder, S; Voigt, R, 1985
)
0.81
"Examining blood level values and urinary concentrations taken from pregnant and nonpregnant women, the pharmacokinetic dates of azlocillin have been evaluated."( [Pharmacokinetic studies of azlocillin in pregnancy].
Brandstädt, A; Patsch, R; Peiker, G; Schröder, S; Voigt, R,
)
0.63
" Since both drugs were tested with the same dosis in the same subjects, their pharmacokinetic parameters could be compared: mezlocillin, being more lipophilic than azlocillin, showed a higher volume of distribution and therefore lower serum concentrations."( [The effect of infusion rate on pharmacokinetic parameters of azlocillin and mezlocillin].
Adam, D; Frank, U; Haen, E; Remien, J; Richter, E, 1985
)
0.71
" The same applied to the serum half-life (t 1/2), whereas the total body clearance was reduced."( Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin.
Bergan, T; Steingrimsson, O; Thorsteinsson, SB, 1982
)
0.54
" Its plasma half-life varies from 45 to 75 min according to different authors."( [Clinical pharmacokinetics of azlocillin].
Haegel, C; Singlas, E, 1984
)
0.56
" Pharmacokinetic constants were calculated using an open two-compartment model."( [Pharmacokinetics of azlocillin in the burn patient].
Courtieu, AL; Drugeon, HB; Pannier, M, 1984
)
0.59
" There was also a tendency towards longer serum half-life values and excretion of more unchanged compound as the doses increase."( Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.
Bergan, T, 1983
)
0.51
" Serum pharmacokinetic data on the individual patients are computer derived using a modified open two-compartment model."( [Pharmacokinetic studies on the penetration of azlocillin and mezlocillin into bone and tissue fluid (author's transl)].
Schassan, HH; Seidel, H; Wittmann, DH, 1981
)
0.52
"A pharmacokinetic and clinical study was done in 25 newborn infants suffering predominantly from pseudomonas infections treated with azlocillin."( Pharmacokinetics and clinical aspects of azlocillin in paediatrics.
Heimann, G, 1983
)
0.74
"Systemic and urinary pharmacokinetic studies of the disposition of azlocillin were performed in seven male and six female healthy volunteers."( Pharmacokinetics of azlocillin in normal renal function: single and repetitive dosing studies.
Delgado, FA; Stout, RL; Whelton, A, 1983
)
0.83
" Pharmacokinetic parameters were determined by noncompartmental analysis."( Azlocillin pharmacokinetics in patients with cystic fibrosis.
Bosso, JA; Herbst, JJ; Matsen, JM; Saxon, BA, 1984
)
1.71
" After intravenous bolus injection of 15 and 30 mg/kg doses, pharmacokinetic data were calculated, using a two-compartment open body model."( Pharmacokinetics of azlocillin in healthy subjects.
Fillastre, JP; Humbert, G; Leroy, A, 1981
)
0.59
" The serum concentrations of azlocillin were analysed using a two-compartment model, and the pharmacokinetic constants were calculated by a computer."( [Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].
Dvorácek, K; Janků, I; Krebs, V; Modr, Z, 1982
)
1.47
"Inadequate therapeutic results in the treatment of bacterial infections in patients with Cystic Fibrosis prompted a reevaluation of pharmacokinetic parameters of orally and parenterally administered drugs in these patients."( [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].
Guggenbichler, JP; Pillwein, K; Rohrer, R; Schabel, F, 1981
)
0.26
" After intravenous bolus injection of a single dose of 30 mg/kg in normal subjects, pharmacokinetic data were calculated, using a two-compartment open body model."( Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
Fillastre, JP; Godin, M; Humbert, G; Leroy, A, 1980
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"6%) neonates reached their pharmacokinetic target and only two neonates experienced adverse events (feeding intolerance and abnormal liver function), possibly related to azlocillin."( Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study.
Allegaert, K; Gao, Q; Huang, X; Jacqz-Aigrain, E; Kong, L; Li, X; Shi, HY; Tang, BH; Tian, XY; van den Anker, J; Wang, T; Wang, WQ; Wu, YE; Yang, HL; Yao, BF; Zhao, W, 2021
)
1.06

Compound-Compound Interactions

The antibacterial activity of ciprofloxacin, either alone or in combination with azlocillin, imipenem, mezlocillin or tobramycin, was tested against enterococcus and pseudomonas species. A comparative study was made on tobamycin combined with either carb.

ExcerptReferenceRelevance
"The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species."( In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.
Daschner, FD; Langmaack, H; Steffens, A, 1979
)
0.26
"The efficacy of ciprofloxacin alone and in combination with azlocillin was compared with that of azlocillin plus tobramycin in a rat model of aortic valve endocarditis due to Pseudomonas aeruginosa."( Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.
Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin, C,
)
0.62
" The patients received 24 courses of netilmicin (10 mg/kg/day) in combination with azlocillin (600 mg/kg/day), cefsulodin (200 mg/kg/day) or ceftazidime (150 mg/kg/day) for 9-14 days."( Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis.
Hjelte, L; Malmborg, AS; Strandvik, B, 1989
)
0.5
" MICs and MBCs of netilmicin alone and combined with azlocillin, mezlocillin and imipenem were studied."( In vitro activity of netilmicin alone and in combination with azlocillin, mezlocillin and imipenem against 149 coagulase-negative staphylococci.
Allocati, N; Cellini, L; D'Antonio, D; D'Eletto, MR; Di Girolamo, A; Piccolomini, R; Ravagnan, G, 1989
)
0.77
" We conclude that ceftazidime should be given in combination with a conventional full course of an aminoglycoside (amikacin) when used for the empirical treatment of gram-negative bacteremia in cancer patients with granulocytopenia."( Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
Calandra, T; Gaya, H; Glauser, MP; Klastersky, J; Meunier, F; Zinner, SH, 1987
)
0.27
"An in-vitro pharmacokinetic model was used to study the bactericidal activity of ciprofloxacin, alone and in combination with azlocillin."( Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.
Dudley, MN; Zinner, SH, 1986
)
0.71
"The antibacterial activity of ciprofloxacin, either alone or in combination with azlocillin, imipenem, mezlocillin or tobramycin, was tested against enterococcus and pseudomonas species."( [Ciprofloxacin in combination with other antimicrobial substances].
Mellinghoff, D; Shah, PM; Stille, W, 1988
)
0.5
"Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 10(6) CFU/ml."( Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
Andriole, VT; Downs, JT; Ryan, JL,
)
0.69
" Evaluation of therapeutic efficacy of ureidopenicillins combined with sisomicin was performed on 90 rabbits, infected intravenously with heavy inocula."( In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
Dzierzanowska, D; Jeljaszewicz, J, 1983
)
0.52
"The MIC and MBC activity of mezlocillin alone and in combination with two concentrations of ceftizoxime, moxalactam, and amikacin and a single concentration of cefoxitin was studied in a broth microdilution partial checkerboard against 472 strains of aerobic gram-negative and gram-positive bacteria."( In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.
Gerding, DN; Moody, JA; Peterson, LR, 1984
)
0.27
"Aztreonam, a synthetic monobactam antimicrobial agent specifically active against aerobic, gram-negative microorganisms, was studied in combination with the extended-spectrum penicillins azlocillin and piperacillin against 46 strains of Pseudomonas aeruginosa."( Effect of aztreonam in combination with azlocillin or piperacillin on Pseudomonas aeruginosa.
Baltch, AL; Conley, PE; Smith, RP; Wu, DH, 1984
)
0.73
"A comparative study was made on tobramycin combined with either carbenicillin (500 mg/kg/day) or one of the new penicillins: azlocillin or piperacillin (both 300 mg/kg/day) in 50 cystic fibrosis patients with chronic Pseudomonas aeruginosa infection."( Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.
Eriksen, KR; Feddersen, C; Flensborg, EW; Høiby, N; Møller, NE; Norn, S; Rosendal, K; Schiøtz, PO; Skov, PS, 1982
)
0.69

Bioavailability

ExcerptReferenceRelevance
" However, bioavailability was comparatively lower in veins due to higher levels in arteries during the distribution phase."( [Bone and blood levels of azlocillin after intra-arterial injection in the dog].
Choisy, C; Choisy, H; Lamiable, D; Millart, H, 1984
)
0.57

Dosage Studied

We have developed an azlocillin dosing nomogram suitable for use in patients with various degrees of renal functional impairment. The response rate to once-daily gentamicin dosing and Azlocillin was three times higher than to multiple- daily gentamicine dosing. No significant systemic accumulation of az Locillin was noted during the repetitive dosing study.

ExcerptRelevanceReference
"The pharmacodynamics of amikacin given as a single daily dose was compared with standard divided dosing in an in-vitro model of infection."( Single daily dosing of amikacin in an in-vitro model.
Dudley, MN; Zinner, SH, 1991
)
0.28
" Studies with the two drugs in combination were compared using simultaneous or staggered (first doses of each drug were administered 6 h apart) dosing schedules."( Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.
Blaser, J; Dudley, MN; Gilbert, D; Mayer, KH; Zinner, SH, 1991
)
0.54
" Microtiter checkerboard technique was compared with standard killing curve method and with killing curves obtained in kinetic in vitro models mimicking single or multiple dosing regimens according to human pharmacokinetics."( Interactions of antimicrobial combinations in vitro: the relativity of synergism.
Blaser, J, 1990
)
0.28
" Ceftriaxone had the considerable practical advantages of once daily dosage without a need for blood monitoring."( Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children.
Smith, L; Stevens, RF; Will, AM; Williams, RF, 1990
)
0.63
" Apparently, continuous arteriovenous hemofiltration has no clinically relevant implications for the dosage or the dosage intervals of this antibiotic."( [The effect of continuous arteriovenous hemofiltration on the pharmacokinetics of azlocillin in anuric patients].
Eberhardt, B; Krupp, A; Leuwer, M; Schmidt, H, 1990
)
0.5
" A procedure for design of azlocillin individual dosage regimens based on calculating individual clearance by the "patient factors" is described."( [Pharmacokinetics of azlocillin in critical conditions: an individualized schedule of drug administration in relation to anatomo-physiologic and pathologic factors].
Firsov, AA; Kruglov, AA; Mura'veva, SA; Nasonov, VN, 1989
)
0.89
" Higher dosage of 200 mg/kg body weight and monitoring of plasma drug levels are recommended in the therapy of patients with cystic fibrosis."( [Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications].
Bartolozzi, G; Marianelli, L; Rosselli, P; Valenza, T,
)
1.04
"To compare the multiple-dose pharmacokinetics of two dosage regimens of azlocillin, we studied 12 healthy volunteers via a randomized, crossover design with a 2-week washout phase between regimens."( Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.
Henderson, RP; Lander, RD; Pyszczynski, DR, 1989
)
0.78
" The results, discussed with the dates given by literature, allow us to state that it is not necessary to change dosage and application interval of azlocillin during pregnancy."( [The pharmacokinetics of azlocillin after single and multiple intravenous injections during the third trimester].
Brandstädt, A; Peiker, G; Schröder, S; Voigt, R; Weidt, I, 1988
)
0.78
" The highly dosed antibiotics were well tolerated and emergence of resistance was rarely observed."( Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin.
Desgrandchamps, D; Kraemer, R; Schaad, UB, 1986
)
0.48
" Against a strain of Pseudomonas aeruginosa, ciprofloxacin in clinically achievable dosing schedules produced a rapid bactericidal effect, but bacterial regrowth occurred."( Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.
Dudley, MN; Zinner, SH, 1986
)
0.51
"1 to 138 micrograms/g tissue) require a higher dosage to ensure sufficient antimicrobial therapy in all patients."( Concentration of azlocillin in human chondral tissue.
Bremm, KD; Knöller, J; König, W; Meier, H; Schönfeld, W, 1988
)
0.61
" Dosage varied according to severity of disease, body size, and the susceptibility of the Pseudomonas isolate to ciprofloxacin; the dose ranged from 750 to 2,250 mg daily (mean, 1,800 mg)."( Ciprofloxacin therapy in cystic fibrosis.
Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987
)
0.27
" Equivalent antibiotic dosing was based on the time rat serum antibiotic levels were above the minimal bactericidal concentration for the challenge organism."( Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.
Johnson, DE; Thompson, B, 1986
)
0.54
" Elimination halflives (t1/2 beta) were highly variable (62-1, 194 min), but no significant increase occurred in patients with stable renal function during repetitive dosage due to previously described nonlinear pharmacokinetic behavior of azlocillin."( Azlocillin serum levels on repetitive dosage in patients with normal and abnormal renal function.
Follath, F; Wenk, M, 1986
)
1.9
" A total daily dosage of 300 mg/kg or 9 gm/m2 given in four to six divided dosages should produce peak concentrations of approximately 150 micrograms/ml, and concentrations greater than 16 micrograms/ml for at least 2 hours after each administration."( Clinical pharmacology of extended-spectrum penicillins in infants and children.
Koup, JR; Wilson, CB, 1985
)
0.27
" Therefore we state: It is not necessary to change the dosage and the application interval of azlocillin during pregnancy."( [Pharmacokinetic studies of azlocillin in pregnancy].
Brandstädt, A; Patsch, R; Peiker, G; Schröder, S; Voigt, R,
)
0.64
" During a steady-state dosing interval, a dose of azlocillin was coadministered with a 10-mg/kg dose of iothalamate sodium as a 30-minute infusion."( Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis.
Goldmann, D; Hilman, BC; Koup, JR; Smith, AL; Williams-Warren, J; Woolf, RA,
)
0.67
" The fact that it increases slightly with dosage suggests the kinetics of the drug might be dose-dependent."( [Clinical pharmacokinetics of azlocillin].
Haegel, C; Singlas, E, 1984
)
0.56
" These results are comparable to those found in the literature and can be used as a basis for adjusting azlocillin dosage to the degree of renal function."( [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
Fillastre, JP; Godin, M; Humbert, G; Leroy, A, 1984
)
0.8
" Dosage was 240 mg/kg/24 h in three intravenous infusions in adults and in children older than 3 months, and 75 to 225 mg/kg/24 h in two intravenous injections in neonates and prematures."( [Evaluation of the clinical activity of azlocillin. A multicenter study conducted in 14 centers].
Konopka, CA, 1984
)
0.54
" On the basis of these findings, CTX dosage adjustment is recommended only in patients with a glomerular filtration rate (GFR) below 20 ml/min."( Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
Borner, K; Kampf, D; Kessel, M; Möller, M, 1984
)
0.56
" Dosage modifications only to one-third of normal are needed for a renal clearance of 10-25 ml/min."( Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.
Bergan, T, 1983
)
0.51
" Twenty-six patients were valid for final analysis of their therapeutic results; 12 treated with azlocillin (group I) at mean dosage of 252 mg/kg/day for a mean duration of 13."( Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study.
Braverman, S; Goldberg, M; Huang, NN; Keith, H; Palmer, J; Schidlow, D, 1983
)
0.74
" Using this dosage non-linear kinetics and an accumulation of the drug would not occur."( Pharmacokinetics and clinical aspects of azlocillin in paediatrics.
Heimann, G, 1983
)
0.53
" Intravenous administration of the antibiotic at a mean dosage of 17 g/day for 6 to 59 days resulted in an excellent or good clinical response in 90% (19) of the patients treated."( Treatment of serious Pseudomonas infections with azlocillin.
Beville, R; Holmes, B; Mogabgab, WJ; Olive, S; Pauling, B; Pollock, B, 1983
)
0.52
"This prospective, controlled, randomized double blind study compared the safety and effectiveness of intravenous azlocillin at a dosage of 6 g/day in three divided doses with that of intravenous ticarcillin at 8 g/day in four divided doses for the treatment of urinary tract infections in 35 patients."( Comparison of azlocillin and ticarcillin in the treatment of urinary tract infection.
Palmer, DL; Reed, WP, 1983
)
0.84
" No significant systemic accumulation of azlocillin was noted during the repetitive dosing study."( Pharmacokinetics of azlocillin in normal renal function: single and repetitive dosing studies.
Delgado, FA; Stout, RL; Whelton, A, 1983
)
0.86
"We have developed an azlocillin dosing nomogram suitable for use in patients with various degrees of renal functional impairment."( An azlocillin dosing nomogram for renal insufficiency.
Delgado, FA; Stout, RL; Whelton, A, 1983
)
1.21
" Elimination-constant halflife, distribution volume and area under the curve were determined to propose dosage recommendations."( [Experiences using acylureido-penicillins (azlocillin, mezlocillin) in pediatrics].
Patsch, R; Sitka, U; Thiemann, HH; Weingärtner, L,
)
0.39
"0% after the lower and higher dosage of furazlocillin, with significant inter- and intrasubject variability."( The pharmacokinetics of furazlocillin in healthy humans.
Förster, D; Gau, W; Gundert-Remy, U; Hinderling, PH, 1983
)
0.83
" The results of our studies, together with the data on the in vitro and in vivo activity of azlocillin and gentamicin and the applicable dosage for clinical purposes, indicate that the azlocillin levels in the perilymph are considerably more effective against Pseudomonas aeruginosa and many times more effective against the other microorganisms usually involved in acute otitis media than those of the aminoglycosides."( The pharmacokinetics of azlocillin in the perilymph of guinea pigs and otitis media.
Federspil, P, 1982
)
0.79
" On the basis of these studies, a dosage schedule for azlocillin has been established."( Pharmacokinetics of azlocillin in neonates.
Patsch, R; Richter, I; Sitka, U; Weingärtner, L, 1980
)
0.83
" Intraperitoneal injection of immune globulin in high dosage had little effect on our parameters."( [The effect of immunoglobulins in experimental peritonitis (author's transl)].
Eckert, P; Naber, M; Schneider, M, 1980
)
0.26
" The linear relationships between the elimination of half-life (T(1/2beta)) and serum creatinine and the elimination rate constant (beta) and creatinine clearance (C(cr)) provided a basis for adjustment of dosage in renal failure."( Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
Fillastre, JP; Godin, M; Humbert, G; Leroy, A, 1980
)
0.58
"Nowadays, real-world data can be used to improve currently available dosing guidelines and to support regulatory approval of drugs for use in neonates by overcoming practical and ethical hurdles."( Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study.
Allegaert, K; Gao, Q; Huang, X; Jacqz-Aigrain, E; Kong, L; Li, X; Shi, HY; Tang, BH; Tian, XY; van den Anker, J; Wang, T; Wang, WQ; Wu, YE; Yang, HL; Yao, BF; Zhao, W, 2021
)
0.87
" First, a maturational pharmacokinetic-pharmacodynamic model of azlocillin was developed, using an empirical dosing regimen combined with opportunistic samples resulting from waste material."( Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study.
Allegaert, K; Gao, Q; Huang, X; Jacqz-Aigrain, E; Kong, L; Li, X; Shi, HY; Tang, BH; Tian, XY; van den Anker, J; Wang, T; Wang, WQ; Wu, YE; Yang, HL; Yao, BF; Zhao, W, 2021
)
1.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
penicillin allergenAny penicillin which causes the onset of an allergic reaction.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm200.00002.00006.65009.4000AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID523271Lipophilicity, log P of the compound2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID64752Influence of siderophore receptor on antibacterial activity in Escherichia coli (H1877) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID198150In vitro antibacterial activity against GN 12873 strain of Stenotrophomonas maltophilia2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID523273Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID523270Permeability across Escherichia coli HN1157/pHSG576oxa7 assessed as permeability coefficient in presence of proton uncoupler carbonyl cyanide meta-chlorophenylhydrazone2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID64876Influence of siderophore receptor on antibacterial activity in Escherichia coli (H873) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID64742Influence of porins and TonB on antibacterial activity in Escherichia coli (BR158) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID64732Influence of siderophore receptor on antibacterial activity in Escherichia coli (1875) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID523268Activity at Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID151698In vitro antibacterial activity against SG 137 strain of Pseudomonas aeruginosa2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID523272Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa7 assessed as minimal drug concentration2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID64744Influence of siderophore receptor on antibacterial activity in Escherichia coli (H1443) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID151697In vitro antibacterial activity against ATCC 27853 strain of Pseudomonas aeruginosa2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID523269Binding affinity to Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID64890Influence of porins and TonB on antibacterial activity in Escherichia coli (PLB268) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID94143In vitro antibacterial activity against ATCC 100331 strain of Klebsiella pneumoniae2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID64880Influence of porins and TonB on antibacterial activity in Escherichia coli (KB4) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID65369In vitro antibacterial activity against ATCC 25922 strain of Escherichia coli2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID563522Antibacterial activity against Pseudomonas aeruginosa NY219 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID64882Influence of porins and TonB on antibacterial activity in Escherichia coli (KB5) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID563518Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID523266Activity at Escherichia coli isolate 7181 beta-lactamase OXA-72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID563519Antibacterial activity against Pseudomonas aeruginosa NY214 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID64738Influence of porins and TonB on antibacterial activity in Escherichia coli (AB2847) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID64748Influence of siderophore receptor on antibacterial activity in Escherichia coli (H1876) using agar diffusion assay2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID201742In vitro antibacterial activity against SG 621 strain of Serratia marcescens2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID563521Antibacterial activity against Pseudomonas aeruginosa NY217 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1209733Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID563523Antibacterial activity against Pseudomonas aeruginosa NY220 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523274Activity at Escherichia coli isolate 7181 beta-lactamase OXA-7 measured per mg of protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID563520Antibacterial activity against Pseudomonas aeruginosa NY215 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID201428In vitro antibacterial activity against SG 511 strain of Staphylococcus aureus2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (427)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990343 (80.33)18.7374
1990's46 (10.77)18.2507
2000's18 (4.22)29.6817
2010's14 (3.28)24.3611
2020's6 (1.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.48 (24.57)
Research Supply Index6.23 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index71.36 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (44.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (12.20%)5.53%
Reviews13 (2.88%)6.00%
Case Studies22 (4.88%)4.05%
Observational0 (0.00%)0.25%
Other361 (80.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis [NCT03932123]500 participants (Anticipated)Observational2019-05-05Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]